![A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma]()
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaBerenson, J. R.; Matous, J.; Swift, R. A.; Mapes, R.; Morrison, B.; Yeh, H. S. · Clinical Cancer Research · 2007